Cardiovascular Systems Profit Margin 2006-2020 | CSII
Current and historical gross margin, operating margin and net profit margin for Cardiovascular Systems (CSII) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Cardiovascular Systems net profit margin as of March 31, 2020 is -4.04%.
|Cardiovascular Systems Annual Profit Margins
|Cardiovascular Systems Quarterly Profit Margins
||Medical Products Manufacturing
Cardiovascular Systems, Inc., formerly known as Replidyne Inc., is headquartered in Saint Paul, Minnesota. It is a medical device company focusing on developing and commercializing interventional treatment systems for vascular disease. Its initial product, the Diamondback 360? Orbital Atherectomy System, is a minimally invasive catheter system for the treatment of peripheral arterial disease; and a range of plaque types, including calcified vessel lesions. The Diamondback 360? removes soft and calcified plaque in plaque-lined vessels through the orbital rotation of a diamond grit coated offset crown. The company refined its `orbital` technology to address the growing market need of providing a safer more effective atherectomy device.